Metal catalyzed oxidation of alpha-synuclein - A role for oligomerization in pathology?

Current Alzheimer Research

Volumn 5, Issue 6, 2008, Pages 599-606

  Cole, N B ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Alpha synuclein; Cross linking; Dopamine; Metals; Neuromelanin; Oligomerization; Oxidation; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; CATECHOL DERIVATIVE; CATECHOLAMINE; POLYPHENOL DERIVATIVE; TRANSITION ELEMENT;

CATALYSIS; CELL INCLUSION; CHEMICAL REACTION; CHEMICAL STRUCTURE; HUMAN; IMMUNOBLOTTING; LEWY BODY; LIPID OXIDATION; MESENCEPHALON; NERVE DEGENERATION; NEURITE; NONHUMAN; OLIGOMERIZATION; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN CROSS LINKING; REVIEW;

ALPHA-SYNUCLEIN; ANIMALS; BRAIN CHEMISTRY; CATALYSIS; HUMANS; LIPID PEROXIDATION; METALS; NEURODEGENERATIVE DISEASES; OXIDATION-REDUCTION;

EID: 58149166860     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720508786898523     Document Type: Review

References (120)

1. Braak H, Muller CM, Rub U, Ackermann H, Bratzke H, de Vos RA, et al. Pathology associated with sporadic Parkinson's disease-where does it end? J Neural Transm Suppl 70:89-97 (2006).
2. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. Controversies over the staging of alpha-synuclein pathology in Parkinson's disease. Acta Neuropathol 116:125-8 (2008).
3. Braak H, Del Tredici K. Reply to "Controversies over the staging of alpha-synuclein pathology in Parkinson's disease". Acta Neuropathol 116:129-31 (2008).
4. Jellinger KA. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol 116:1-16 (2008).
5. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 53 Suppl 3: S26-36; discussion S36-8 (2003).
6. Abou-Sleiman PM, Muqit MM, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 7:207-19 (2006).
7. Graham DG, Tiffany SM, Bell WR, Jr., Gutknecht WF. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 14:644-53 (1978).
8. Lotharius J, Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 3: 932-42 (2002).
9. Swartz HM, Sarna T, Zecca L. Modulation by neuromelanin of the availability and reactivity of metal ions. Ann Neurol 32 (Suppl): S69-75 (1992).
10. D'Amato RJ, Lipman ZP, Snyder SH. Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. Science 231:987-9 (1986).
11. Zecca L, Pietra R, Goj C, Mecacci C, Radice D, Sabbioni E, et al. Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain. J Neurochem 62:1097-101 (1994).
12. Zecca L, Zucca FA, Wilms H, Sulzer D. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci 26: 578-80 (2003).
13. Fedorow H, Pickford R, Hook JM, Double KL, Halliday GM, Gerlach M, et al. Dolichol is the major lipid component of human substantia nigra neuromelanin. J Neurochem 92:990-5 (2005).
14. Bergamini E, Bizzarri R, Cavallini G, Cerbai B, Chiellini E, Donati A, et al. Ageing and oxidative stress: a role for dolichol in the antioxidant machinery of cell membranes? J Alzheimers Dis 6:129-35 (2004).
15. Wong TK, Decker GL, Lennarz WJ. Localization of dolichol in the lysosomal fraction of rat liver. J Biol Chem 257:6614-8 (1982).
16. Juurlink BH. Lysosomal accumulation of neuromelanin-like material in astrocytes after exposure to norepinephrine. J Neuropathol Exp Neurol 47:48-53 (1988).
17. Tribl F, Gerlach M, Marcus K, Asan E, Tatschner T, Arzberger T, et al. "Subcellular proteomics" of neuromelanin granules isolated from the human brain. Mol Cell Proteomics 4:945-57 (2005).
18. Barden H. Relationship of golgi thiaminepyrophosphatase and lysosomal acid phosphatase to neuromelanin and lipofuscin in cerebral neurons of the aging rhesus monkey. J Neuropathol Exp Neurol 29:225-40 (1970).
19. Sulzer D, Mosharov E, Talloczy Z, Zucca FA, Simon JD, Zecca L. Neuronal pigmented autophagic vacuoles: lipofuscin, neuromelanin, and ceroid as macroautophagic responses during aging and disease. J Neurochem 106:1-16 (2008).
20. Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334:345-8 (1988).
21. Wright JA, Brown DR. Alpha-synuclein and its role in metal binding: relevance to Parkinson's disease. J Neurosci Res 86:496-503 (2008).
22. Gerlach M, Double KL, Youdim MB, Riederer P. Potential sources of increased iron in the substantia nigra of parkinsonian patients. J Neural Transm Suppl:133-42 (2006).
23. Sayre LM, Moreira PI, Smith MA, Perry G. Metal ions and oxidative protein modification in neurological disease. Ann Ist Super Sanita 41:143-64 (2005).
24. Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74:199-205 (1988).
25. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52:515-20 (1989).
26. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114(Pt 4):1953-75 (1991).
27. Double KL, Gerlach M, Youdim MB, Riederer P. Impaired iron homeostasis in Parkinson's disease. J Neural Transm Suppl:37-58 (2000).
28. Faucheux BA, Martin ME, Beaumont C, Hauw JJ, Agid Y, Hirsch EC. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J Neurochem 86:1142-8 (2003).
29. Ben-Shachar D, Youdim MB. Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J Neurochem 57:2133-5 (1991).
30. Sengstock GJ, Olanow CW, Menzies RA, Dunn AJ, Arendash GW. Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers. J Neurosci Res 35:67-82 (1993).
31. Fasano M, Bergamasco B, Lopiano L. Modifications of the iron-neuromelanin system in Parkinson's disease. J Neurochem 96:909-16 (2006).
32. He Y, Thong PS, Lee T, Leong SK, Mao BY, Dong F, et al. Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys. Free Radic Biol Med 35:540-7 (2003).
33. Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37:899-909 (2003).
34. Lee DW, Andersen JK, Kaur D. Iron dysregulation and neurodegeneration: the molecular connection. Mol Interv 6:89-97 (2006).
35. Barbeau A. Manganese and extrapyramidal disorders (a critical review and tribute to Dr. George C. Cotzias). Neurotoxicology 5:13-35 (1984).
36. Graham DG. Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease. Neurotoxicology 5:83-95 (1984).
37. Lloyd RV. Mechanism of the manganese-catalyzed autoxidation of dopamine. Chem Res Toxicol 8:111-6 (1995).
38. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, et al. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 20:239-47 (1999).
39. Pall HS, Williams AC, Blake DR, Lunec J, Gutteridge JM, Hall M, et al. Raised cerebrospinal-fluid copper concentration in Parkinson's disease. Lancet 2:238-41 (1987).
40. Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A. Genetics of Parkinson's disease and parkinsonism. Ann Neurol 60:389-98 (2006).
41. Thomas B, Beal MF. Parkinson's disease. Hum Mol Genet 16 Spec No. 2:R183-94 (2007).
42. Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 7:306-18 (2006).
43. Jellinger KA. Neuropathological spectrum of synucleinopathies. Mov Disord 18 (Suppl 6):S2-12 (2003).
44. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT, Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35:13709-15 (1996).
45. Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 273:9443-9 (1998).
46. Tofaris GK, Spillantini MG. Physiological and pathological properties of alpha-synuclein. Cell Mol Life Sci 64:2194-201 (2007).
47. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 4:1318-20 (1998).
48. Conway KA, Harper JD, Lansbury PT, Jr. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39:2552-63 (2000).
49. Giasson BI, Uryu K, Trojanowski JQ, Lee VM. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem 274:7619-22 (1999).
50. Kahle PJ, Neumann M, Ozmen L, Muller V, Odoy S, Okamoto N, et al. Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol 159:2215-25 (2001).
51. Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, et al. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 -> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci USA 99:8968-73 (2002).
52. Li W, West N, Colla E, Pletnikova O, Troncoso JC, Marsh L, et al. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci USA 102:2162-7 (2005).
53. Campbell BC, Li QX, Culvenor JG, Jakala P, Cappai R, Beyreuther K, et al. Accumulation of insoluble alpha-synuclein in dementia with Lewy bodies. Neurobiol Dis 7:192-200 (2000).
54. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281:29739-52 (2006).
55. Volles MJ, Lansbury PT, Jr. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 42:7871-8 (2003).
56. Hasegawa M, Fujiwara H, Nonaka T, Wakabayashi K, Takahashi H, Lee VM, et al. Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem 277:49071-6 (2002).
57. Uversky VN, Li J, Fink AL. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem 276:44284-96 (2001).
58. Uversky VN, Li J, Fink AL. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem 276:10737-44 (2001).
59. Goers J, Uversky VN, Fink AL. Polycation-induced oligomerization and accelerated fibrillation of human alpha-synuclein in vitro. Protein Sci 12:702-7 (2003).
60. Fernandez CO, Hoyer W, Zweckstetter M, Jares-Erijman EA, Subramaniam V, Griesinger C, et al. NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation. EMBO J 23:2039-46 (2004).
61. Bernado P, Bertoncini CW, Griesinger C, Zweckstetter M, Blackledge M. Defining long-range order and local disorder in native alpha-synuclein using residual dipolar couplings. J Am Chem Soc 127:17968-9 (2005).
62. Dedmon MM, Lindorff-Larsen K, Christodoulou J, Vendruscolo M, Dobson CM. Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. J Am Chem Soc 127:476-7 (2005).
63. Lee JC, Lai BT, Kozak JJ, Gray HB, Winkler JR. Alpha-synuclein tertiary contact dynamics. J Phys Chem B 111:2107-12 (2007).
64. Bertoncini CW, Jung YS, Fernandez CO, Hoyer W, Griesinger C, Jovin TM, et al. Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc Natl Acad Sci USA 102:1430-5 (2005).
65. Rasia RM, Bertoncini CW, Marsh D, Hoyer W, Cherny D, Zweckstetter M, et al. Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease. Proc Natl Acad Sci USA 102:4294-9 (2005).
66. Binolfi A, Rasia RM, Bertoncini CW, Ceolin M, Zweckstetter M, Griesinger C, et al. Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. J Am Chem Soc 128:9893-901 (2006).
67. Sung YH, Rospigliosi C, Eliezer D. NMR mapping of copper binding sites in alpha-synuclein. Biochim Biophys Acta 1764:5-12 (2006).
68. Kowalik-Jankowska T, Rajewska A, Wisniewska K, Grzonka Z, Jezierska J. Coordination abilities of N-terminal fragments of alpha-synuclein towards copper(II) ions: a combined potentiometric and spectroscopic study. J Inorg Biochem 99:2282-91 (2005).
69. Liu LL, Franz KJ. Phosphorylation-dependent metal binding by alpha-synuclein peptide fragments. J Biol Inorg Chem 12:234-47 (2007).
70. Miller DM, Buettner GR, Aust SD. Transition metals as catalysts of "autoxidation" reactions. Free Radic Biol Med 8:95-108 (1990).
71. Welch KD, Davis TZ, Aust SD. Iron autoxidation and free radical generation: effects of buffers, ligands, and chelators. Arch Biochem Biophys 397:360-9 (2002).
72. Halliwell B, Gutteridge JM. Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch Biochem Biophys 246:501-14 (1986).
73. Berlett BS, Stadtman ER. Protein oxidation in aging, disease, and oxidative stress. J Biol Chem 272:20313-6 (1997).
74. Welch KD, Davis TZ, Van Eden ME, Aust SD. Deleterious iron-mediated oxidation of biomolecules. Free Radic Biol Med 32:577-83 (2002).
75. Buettner GR, Jurkiewicz BA. Catalytic metals, ascorbate and free radicals: combinations to avoid. Radiat Res 145:532-41 (1996).
76. Stadtman ER, Levine RL. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids 25:207-18 (2003).
77. Paik SR, Shin HJ, Lee JH. Metal-catalyzed oxidation of alpha-synuclein in the presence of Copper(II) and hydrogen peroxide. Arch Biochem Biophys 378:269-77 (2000).
78. Norris EH, Giasson BI, Ischiropoulos H, Lee VM. Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J Biol Chem 278:27230-40 (2003).
79. Cole NB, Murphy DD, Lebowitz J, Di Noto L, Levine RL, Nussbaum RL, et al. Metal-catalyzed oxidation of alpha-synuclein: helping to define the relationship between oligomers, protofibrils, and filaments. J Biol Chem 280:9678-90 (2005).
80. Stadtman ER. Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Annu Rev Biochem 62:797-821 (1993).
81. Kostka M, Hogen T, Danzer KM, Levin J, Habeck M, Wirth A, et al. Single Particle Characterization of Iron-induced Pore-forming {alpha}-Synuclein Oligomers. J Biol Chem 283:10992-11003 (2008).
82. Moncada C, Israel Y. Protein binding of alpha-hydroxyethyl free radicals. Alcohol Clin Exp Res 25:1723-8 (2001).
83. Sevanian A, Hochstein P. Mechanisms and consequences of lipid peroxidation in biological systems. Annu Rev Nutr 5:365-90 (1985).
84. Minotti G, Aust SD. The role of iron in oxygen radical mediated lipid peroxidation. Chem Biol Interact 71:1-19 (1989).
85. Halliwell B, Gutteridge JM. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 219:1-14 (1984).
86. Greco A, Minghetti L, Levi G. Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. Neurochem Res 25:1357-64 (2000).
87. Montine KS, Quinn JF, Zhang J, Fessel JP, Roberts LJ, 2nd, Morrow JD, et al. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids 128:117-24 (2004).
88. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11:81-128 (1991).
89. Sayre LM, Perry G, Smith MA. Oxidative stress and neurotoxicity. Chem Res Toxicol 21:172-88 (2008).
90. Qin Z, Hu D, Han S, Reaney SH, Di Monte DA, Fink AL, et al. Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J Biol Chem 282:5862-70 (2007).
91. Trostchansky A, Lind S, Hodara R, Oe T, Blair IA, Ischiropoulos H, et al. Interaction with phospholipids modulates alpha-synuclein nitration and lipid-protein adduct formation. Biochem J 393:343-9 (2006).
92. Shamoto-Nagai M, Maruyama W, Hashizume Y, Yoshida M, Osawa T, Riederer P, et al. In parkinsonian substantia nigra, alpha-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity. J Neural Transm 114:1559-67 (2007).
93. Morrison M, Steele W, Danner DJ. The reaction of benzoquinone with amines and proteins. Arch Biochem Biophys 134:515-23 (1969).
94. Tse DC, McCreery RL, Adams RN. Potential oxidative pathways of brain catecholamines. J Med Chem 19:37-40 (1976).
95. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14:633-43 (1978).
96. Sulzer D, Zecca L. Intraneuronal dopamine-quinone synthesis: a review. Neurotox Res 1:181-95 (2000).
97. Conway KA, Rochet JC, Bieganski RM, Lansbury PT, Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294:1346-9 (2001).
98. Li HT, Lin DH, Luo XY, Zhang F, Ji LN, Du HN, et al. Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration. FEBS J 272:3661-72 (2005).
99. Cappai R, Leck SL, Tew DJ, Williamson NA, Smith DP, Galatis D, et al. Dopamine promotes alpha-synuclein aggregation into SDSresistant soluble oligomers via a distinct folding pathway. FASEB J 19:1377-9 (2005).
100. Li J, Zhu M, Manning-Bog AB, Di Monte DA, Fink AL. Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J 18:962-4 (2004).
101. Norris EH, Giasson BI, Hodara R, Xu S, Trojanowski JQ, Ischiropoulos H, et al. Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J Biol Chem 280:21212-9 (2005).
102. Bisaglia M, Mammi S, Bubacco L. Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. J Biol Chem 282:15597-605 (2007).
103. Burke WJ, Kumar VB, Pandey N, Panneton WM, Gan Q, Franko MW, et al. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol 115:193-203 (2008).
104. Zhu M, Rajamani S, Kaylor J, Han S, Zhou F, Fink AL, et al. The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. J Biol Chem 279:26846-57 (2004).
105. Yoshino M, Murakami K. Interaction of iron with polyphenolic compounds: application to antioxidant characterization. Anal Biochem 257:40-4 (1998).
106. Schweigert N, Zehnder AJ, Eggen RI. Chemical properties of catechols and their molecular modes of toxic action in cells, from microorganisms to mammals. Environ Microbiol 3:81-91 (2001).
107. Hunt JV, Bottoms MA, Mitchinson MJ. Oxidative alterations in the experimental glycation model of diabetes mellitus are due to protein-glucose adduct oxidation. Some fundamental differences in proposed mechanisms of glucose oxidation and oxidant production. Biochem J 291 (Pt 2):529-35 (1993).
108. Singh R, Barden A, Mori T, Beilin L. Advanced glycation endproducts: a review. Diabetologia 44:129-46 (2001).
109. Dalfo E, Portero-Otin M, Ayala V, Martinez A, Pamplona R, Ferrer I. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 64:816-30 (2005).
110. Munch G, Luth HJ, Wong A, Arendt T, Hirsch E, Ravid R, et al. Crosslinking of alpha-synuclein by advanced glycation endproducts - an early pathophysiological step in Lewy body formation? J Chem Neuroanat 20:253-7 (2000).
111. Shaikh S, Nicholson LF. Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation. J Neurosci Res 86:2071-82 (2008).
112. Cookson MR, van der Brug M. Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp Neurol 209:5-11 (2008).
113. Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 27:9220-32 (2007).
114. Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, Koker M, Carvalho F, et al. Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS ONE 3:e1867 (2008).
115. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486-9 (2003).
116. Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 279:46363-6 (2004).
117. Olanow CW. The pathogenesis of cell death in Parkinson's disease - 2007. Mov Disord 22 (Suppl 17):S335-42 (2007).
118. Kim HJ, Chatani E, Goto Y, Paik SR. Seed-dependent accelerated fibrillation of alpha-synuclein induced by periodic ultrasonication treatment. J Microbiol Biotechnol 17:2027-32 (2007).
119. Cabin DE, Gispert-Sanchez S, Murphy D, Auburger G, Myers RR, Nussbaum RL, et al. Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background. Neurobiol Aging 26:25-35 (2005).
120. Stadtman ER. Protein oxidation and aging. Free Radic Res 40:1250-8 (2006).